To test this, mice with subcutaneous CT26.CL25 colon carcinoma tumors were treated with anti-CD4 and anti-CD8 antibodies to deplete CD4+ and CD8+ T-cells before and during the treatment with PBT. This evidence concerns the gene CD4 and colon carcinoma.